Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)
12
4
5
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 50/100
0.0%
0 terminated out of 12 trials
100.0%
+13.5% vs benchmark
8%
1 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 2 completed trials
Clinical Trials (12)
Evaluating the Pharmacokinetics and Safety of Miricorilant
A Trial to Learn if ALN-PNP is Safe and Well Tolerated in Healthy Adults and Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD
SAMe for Prevention of Liver Cancer in MASLD-Related Cirrhosis
The Effect of the DASH Diet on Clinical and Metabolic Parameters in Children With MASLD
Study on Risk Factors and Prognosis of MASLD
Evaluation of Miricorilant on Liver Fat in Patients With MASLD
Stimulating Fat Tissue Storage With Niacin to Reduce Fat Accumulation in the Liver.
A Single-Ascending and Repeated Dose Study of LY3849891 in Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Fibrosis Lessens After Metabolic Surgery
A Study to Predict Recompensation in Patients With Decompensated Cirrhosis Using Spleen Stiffness and Simple Blood Tests
New Non-invasive Biomarkers of Metabolic Dysfunction-associated Steatotic Liver Disease (MASLD)